Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy

Area of Science:

• Oncolytic virotherapy
• Cancer immunotherapy
• Adenovirus vector engineering

Background:

• Murine breast cancer cell lines were identified to support adenovirus replication.
• Oncolytic adenovirus (Ad.IR-E1A/TRAIL) effectively kills tumor cells in a replication-dependent manner.
• Adenovirus vector injection induces pro-inflammatory cytokines, enhancing dendritic cell maturation.

Purpose of the Study:

• To evaluate the combined efficacy of oncolytic adenovirus therapy and dendritic cell mobilization for anti-tumor effects.
• To investigate the systemic anti-tumor immune response induced by viral oncolysis combined with Flt3L or GM-CSF.
• To assess the therapeutic potential of intratumoral injection of combined oncolytic and immunostimulatory adenovirus vectors.

Main Methods:

• Identification of murine breast cancer cell lines supporting adenovirus replication.
• Systemic and intratumoral (i.t.) administration of adenovirus vectors in a syngeneic mouse tumor model (C3H mice, C3L5 tumors).
• In vivo assessment of cytokine and chemokine induction, dendritic cell mobilization (Flt3L, GM-CSF), and tumor growth delay.

Main Results:

• Adenovirus vector injection increased pro-inflammatory cytokines (TNF-alpha, INF-gamma, MCP-1) and induced dendritic cell maturation.
• Adenovirus vector expressing Flt3L increased dendritic cell populations in circulation.
• Combined oncolysis and Flt3L/GM-CSF expression via vaccination induced systemic anti-tumor immunity.
• Intratumoral injection of oncolytic and Flt3L vectors delayed tumor growth but did not achieve complete tumor elimination.

Conclusions:

• Combined oncolytic virotherapy and immunostimulatory adenovirus vectors represent a promising approach for cancer treatment.
• The combination strategy effectively induces systemic anti-tumor immune responses.
• Further optimization is needed for efficient tumor elimination using this combined therapy.